The 1 August 2014 issue of the Schedule of Pharmaceutical Benefits is not available. The new Schedule contains a number of new and revised listings:

• Aclidinium bromide (Bretaris Genuair) - new listing
• Atomoxetine hydrochloride (Strattera) - restriction change
• Betaine (Cystadane) - new listing
• Bevacizumab (Avastin) - new indication
• Corifollitropin alfa (Elonva) - restriction change
• Macrogol 3350 (Movicol Liquid) - new formulation
• Saxagliptin hydrochloride (Onglyza) - new strength
• Epoprostenol sodium (Veletri) - new formulation
• Omalizumab (Xolair) - new formulation
• Progesterone (Endometrin) - new formulation